Kindred Biosciences Inc. [NASDAQ: KIN] stock went on a downward path that fall over -0.43% on Thursday, amounting to a one-week price increase of more than 39.03%. The company report on June 17, 2021 that SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KIN, CNST, MDP, FMBI; Shareholders are Encouraged to Contact the Firm.
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:.
Kindred Biosciences, Inc. (NASDAQ: KIN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Elanco Animal Health Incorporated for $9.25 per share. If you are a Kindred Biosciences shareholder, click here to learn more about your rights and options.
Over the last 12 months, KIN stock rose by 110.78%. The average equity rating for KIN stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $432.48 million, with 41.09 million shares outstanding and 29.85 million shares in the current float. Compared to the average trading volume of 1.01M shares, KIN stock reached a trading volume of 4136964 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Kindred Biosciences Inc. [KIN]:
Aegis Capital have made an estimate for Kindred Biosciences Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 16, 2021. The new note on the price target was released on March 17, 2020, representing the official price target for Kindred Biosciences Inc. stock. Previously, the target price had yet another drop from $17.50 to $16, while H.C. Wainwright kept a Buy rating on KIN stock. On July 16, 2019, analysts decreased their price target for KIN shares from 18 to 8.50.
The Average True Range (ATR) for Kindred Biosciences Inc. is set at 0.61, with the Price to Sales ratio for KIN stock in the period of the last 12 months amounting to 9.83. The Price to Book ratio for the last quarter was 4.50, with the Price to Cash per share for the same quarter was set at 1.34.
KIN Stock Performance Analysis:
Kindred Biosciences Inc. [KIN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 39.03. With this latest performance, KIN shares gained by 94.29% in over the last four-week period, additionally plugging by 120.65% over the last 6 months – not to mention a rise of 110.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KIN stock in for the last two-week period is set at 79.80, with the RSI for the last a single of trading hit 82.88, and the three-weeks RSI is set at 76.91 for Kindred Biosciences Inc. [KIN]. The present Moving Average for the last 50 days of trading for this stock 5.27, while it was recorded at 7.44 for the last single week of trading, and 4.68 for the last 200 days.
Insight into Kindred Biosciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Kindred Biosciences Inc. [KIN] shares currently have an operating margin of -37.29 and a Gross Margin at +83.48. Kindred Biosciences Inc.’s Net Margin is presently recorded at -51.69.
Return on Total Capital for KIN is now -16.10, given the latest momentum, and Return on Invested Capital for the company is -22.62. Return on Equity for this stock declined to -29.18, with Return on Assets sitting at -20.77. When it comes to the capital structure of this company, Kindred Biosciences Inc. [KIN] has a Total Debt to Total Equity ratio set at 34.63. Additionally, KIN Total Debt to Total Capital is recorded at 25.72, with Total Debt to Total Assets ending up at 24.39. Long-Term Debt to Equity for the company is recorded at 31.77, with the Long-Term Debt to Total Capital now at 23.59.
Reflecting on the efficiency of the workforce at the company, Kindred Biosciences Inc. [KIN] managed to generate an average of -$345,968 per employee. Receivables Turnover for the company is 54.51 with a Total Asset Turnover recorded at a value of 0.40.Kindred Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.10 and a Current Ratio set at 12.10.
KIN Stock EPS
With the latest financial reports released by the company, Kindred Biosciences Inc. posted 0.6/share EPS, while the average EPS was predicted by analysts to be reported at 0/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KIN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Kindred Biosciences Inc. go to 40.00%.
Kindred Biosciences Inc. [KIN] Insider Position Details
There are presently around $288 million, or 70.30% of KIN stock, in the hands of institutional investors. The top three institutional holders of KIN stocks are: PARK WEST ASSET MANAGEMENT LLC with ownership of 6,414,985, which is approximately -3.225% of the company’s market cap and around 4.90% of the total institutional ownership; POINT72 ASSET MANAGEMENT, L.P., holding 3,850,200 shares of the stock with an approximate value of $35.38 million in KIN stocks shares; and BLACKROCK INC., currently with $24.95 million in KIN stock with ownership of nearly 1.608% of the company’s market capitalization.
Positions in Kindred Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 42 institutional holders increased their position in Kindred Biosciences Inc. [NASDAQ:KIN] by around 6,813,381 shares. Additionally, 36 investors decreased positions by around 2,530,111 shares, while 18 investors held positions by with 22,045,162 shares. The mentioned changes placed institutional holdings at 31,388,654 shares, according to the latest SEC report filing. KIN stock had 13 new institutional investments in for a total of 5,489,786 shares, while 11 institutional investors sold positions of 174,635 shares during the same period.